Comparative proteomic analysis of the function and network mechanisms of MASPIN in human lung cells

  • Authors:
    • Yao Liu
    • Yi Geng
    • Kuanzhi Li
    • Fang Wang
    • Haiping Zhou
    • Wanhu Wang
    • Jie Hou
    • Wenchao Liu
  • View Affiliations

  • Published online on: December 22, 2011     https://doi.org/10.3892/etm.2011.427
  • Pages: 470-474
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

MASPIN, which is also known as Serpin B5, is a novel tumor suppressor. Emerging evidence suggests that MASPIN acts as a multifaceted protein in various types of cancer, including prostate, breast and pancreatic cancer. It interacts with diverse groups of intercellular and extracellular proteins, regulating cell adhesion, motility, apoptosis and angiogenesis, and is involved in mammary gland development. As MASPIN is a multifunctional factor in cancer pathways, its function remains poorly illuminated. In this study, we compared the protein profiles of LC5 cell lines with MASPIN overexpression and knockdown using comparative two-dimensional gel electrophoresis. The differences in protein expression, visualized as differences in spots, were identified by time‑of‑flight (TOF)/TOF mass spectometry. Significant differences were observed between overexpressing and knocked down cells, including eight spots that were unique and sixteen spots that were up- or down-regulated by more than 4-fold. Six genes, including Sdccag8, Ldoc1, SCAI, SDCCAG3, CT62 and NEDD9 were unique in MASPIN‑expressing cell lines, but absent in knock-out cell lines, in which most of them play a significant role in the invasion of cancer cells. Moreover, the Brms1 and CAGE1 genes were identified as being uniquely expressed in knocked down cell lines, which were associated with the development and progression of tumors. The data from this study shed some light on the function, as well as the general network mechanisms of MASPIN in lung cancer.

Introduction

MASPIN, a novel serine protease inhibitor (Serpin), inhibits tumor invasion and metastasis of mammary carcinoma. The gene encoding MASPIN has been initially identified in a search of genes that display no or down-regulated expression in human breast carcinoma cells (1). This 42-kDa protein is known also as Serpin B5, protease inhibitor-5 or proteinase inhibitor-5. As a tumor suppressor gene, MASPIN is involved in tumor invasion, metastasis and angiogenesis. However, the mechanisms of MASPIN are little known, particularly its signal networks in lung cells.

MASPIN acts as a tumor suppressor gene by impairing tumor growth, cell motility and metastasis. Shi et al demonstrated that MASPIN reduced tumor growth as well as invasion and metastasis through a combination of reduced angiogenesis and increased apoptosis in a transgenic mouse model that overexpressed MASPIN (2). Abraham et al reported that MASPIN increased cell adhesion to the extracellular matrix in prostate tumor cells and that it was capable of decreasing the tumorigenic and metastatic potential of prostate tumors (3). The decreased expression of MASPIN in prostate cancer has also been reported to inversely correlate with the development of local recurrence or systemic tumor progression (4). Furthermore, it has been reported that MASPIN is involved in the processes of embryonic development, apoptosis and angiogenesis. Schaefer and Zhang demonstrated that MASPIN played a significant role in mammary development in a stage-dependent manner (5). The expression levels of MASPIN are lower in virgin and early pregnancy mammary glands than in late pregnancy and lactating mammary glands. Cher et al demonstrated that MASPIN expression inhibited osteolysis, tumor growth and angiogenesis in a model of prostate cancer bone metastasis (6). Finally, the local delivery of MASPIN to human prostate tumor cells in a mouse model blocked tumor growth and dramatically reduced the density of tumor-associated microvessels (5).

Over the past decade, with the expansion of studies on MASPIN, novel protein-binding partners have been identified and have provided insight into the molecular aspects on regulation and divergent mechanisms. Naturally, the MASPIN gene contains a number of potential transcription factor binding elements, which are related to the regulation of its expression. These include activator protein-1 (Ap-1), E26 transformation specific-1 (Ets), hormonal responsive elements (HREs) and p53 binding sites (5). Recently, it has been shown that MASPIN may be affected by promoter methylation levels and by histone modification (7). These data indicate the complexity of the MASPIN network. In this study, we used comparative proteomics to systemically study the protein profile changes in lung cell lines. The large-scale data and system biology methodology may help us to illustrate the function of MASPIN, its regulation pathways and networks in lung cancer.

Materials and methods

Cell culture

The human lung carcinoma cell line, LC5, was kindly provided by the Cell Line Center of the Chinese Academy of Science. The LC5 human lung carcinoma cell line was maintained in RPMI-1640 (Life Technologies, Gaithersburg, MD, USA) with 1 mM glutamate, 100 U/ ml penicillin, 100 ng/ml streptomycin and 10% fetal calf serum (FCS). The cells were cultured at 37°C in a humidified atmosphere of 5% CO2. Cell viability was evaluated by trypan blue exclusion assay.

Porcine cytomegalovirus (pCMV)-maspin construction

For construction of the pCMV-MASPIN plasmid, full-length MASPIN complementary DNA (cDNA) was cloned into the pCMV-Taq4C vector (Invitrogen, Carlsbad, CA, USA), using the primers, 5′-atggatgccctgcaactagca-3′ and 5′-ttaaggagaac agaatttg-3′ (Sangon Co., Shanghai, China).

Transfection of the lung cancer cells

The cells were transfected with small interfering RNA (siRNA) or plasmids using the Effectene (Qiagen, Valencia, CA, USA) or Amaxa electroporation system (Amaxa, Gaithersburg, MD, USA), according to the manufacturer’s instructions. To develop cell lines, which stably expressed MASPIN, following transfection, the cells were then incubated in the medium with Geneticin 418 for 48 h, and selected for 2 weeks. We used a targeted SMART pool of siRNAs from Dharmacon (Lafayette, CO, USA) to knockdown MASPIN expression with the siLentFect lipid kit. In parallel, cells were transfected with a fluorescein isothiocyanate-labeled, nonspecific siRNA with a scrambled sequence.

Western blot analysis

Cells were harvested with ice-cold phosphate-buffered saline and then lysed in lysis buffer containing 10 mM Tris (pH 7.5), 150 mM NaCl, 10 mM ethylenediaminetetraacetic acid, 1% SDS, 1 mM sodium orthovanadate and a mixture of protease inhibitors (Roche, Indianapolis, IN, USA). The lysates were sonicated for 10 sec, centrifuged for 20 min at 20,000 × g, and then stored at −70°C. Equal amounts (25 μg) of the cell lysates were resolved by 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and were subjected to Western blot analysis, using an enhanced chemiluminescence system (Amersham Corp., Arlington Heights, IL, USA).

Two-dimensional gel electrophoresis (2DE) and time-of-flight (TOF)/TOF mass spectometry (MS)

Proteins were collected from LC5 cells as described previously. The extraction buffer included: 9 M urea, 0.5% SDS, 4% CHAPS, 65 mM DTT, nucleases mixture (GE Healthcare, Piscataway, NJ, USA) and protease inhibitor mixture (GE Healthcare). The crude extraction was then treated with Clean-Up Kit (GE Healthcare). The protein (100 μg) was loaded independently using 18 cm pH3–10 (L) stripes by the GE Healthcare 2DE system. Second dimensional SDS-PAGE was carried out, using a 12% gel and stained with the PlusOne Silver Staining Kit (GE Healthcare). The gel images were analyzed by the ImageMaster™ 2D Platinum v7.0 (GE Healthcare). The spots were identified by 6200 Series Accurate-Mass TOF LC/MS (Agilent, Santa Clara, CA, USA).

Results

Overexpression and knockdown of MASPIN in LC5 human lung carcinoma cells

Total RNA was isolated from four exponentially selected cell lines with overexpressed and knocked down MASPIN, respectively. The results suggest that all eight cell lines were successful. All of the transfected cells had a high expression of MASPIN, while MASPIN expression was almost eliminated by siRNA-MASPIN (Fig. 1). Furthermore, the expression of MASPIN protein was confirmed by Western blot analysis. The abundance of MASPIN was detected in the overexpressed cell lines by a specific anti-MASPIN antibody, but was undetectable in the knocked down cell line (Fig. 2). The results indicated that the overexpression or knockdown of MASPIN in LC5 cell lines was successful.

Spot identification by TOF/TOF MS

The global view of a representative two-dimensional gel is shown in Fig. 3. The MASPIN overexpression and knockdown samples were loaded three times. Over 1,400 spots were represented in three duplicates. The excellent reproduction in protein pattern and protein density between all cell lines is evident in the comparison of four 2D gels to each other. All gels were matched to the LC5 cells reference 2D map and the relative density of each protein spot was quantified using ImageMaster software. The data are shown in Table I.

Table I.

Spots identification by TOF/TOF MS.

Table I.

Spots identification by TOF/TOF MS.

Protein nameQuantity in MASPIN overexpression sample (V %)Quantity in MASPIN knockdown sample (V %)Ratio overexpression/knockdown
Sdccag8Unique--
Ldoc1Unique--
SCAIUnique--
SDCCAG3Unique--
CT62Unique--
Brms1Unique--
CAGE1-Unique-
NEDD9-Unique-
TSP10.2880.01224.0
RUNX0.2940.01717.3
ORAOV10.3350.02215.2
PTK20.3960.02416.5
CASC50.4150.0656.38
BCAR10.5830.0886.23
GREB1L0.6760.0967.04
BASE0.6880.1524.54
CTAG20.7070.1694.18
Blcap,0.0770.8350.09
Casc50.0980.7990.12
Casc30.1040.7610.13
Hic20.1120.7330.15
SNCG0.1270.7040.18
HIC10.1440.6980.21
DLC10.1510.6680.23

[i] TOF MS, time-of-flight mass spectrometry.

The results indicate that several tumor suppressor genes are related to the expression of MASPIN. In this study, we have found that at least six genes were unique in MASPIN-overexpressed cell lines, in which most of them play crucial roles in the invasion of cancer cells. For example, the suppressor of cancer cell invasion (SCAI) acts as an inhibitor of cancer cell invasion through the transcriptional control of β1-integrin (8). The serologically defined colon cancer antigen 3 (SDCCAG3) is necessary for the presentation of TNF receptor 1 on the cell surface (9). Leucine zipper, down-regulated in cancer 1 (LDOC1) inhibits NF-κB activation and sensitizes pancreatic cancer cells to apoptosis (10). In addition, breast cancer metastasis suppressor 1 (Brms1) functions as a co-repressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis, and inhibits gene expression by targeting NF-κB activity (11).

However, two genes were discovered to be unique in knockdown cell lines that are associated with the development and progression of tumors. The expression of cancer-associated gene 1 (CAGE1) protein is associated with the progression of tumors and has been used as a response criteria in several tumors during chemotherapy (12). The neural precursor cell expressed developmentally down-regulated protein 9 (NEDD9), as a melanoma metastasis gene, is regulated in human neuroblastoma cells and in the embryonic hindbrain by all-trans retinoic acid (13,14).

Other findings from this study were that nine genes were extremely highly expressed in the MASPIN-overexpressed cell lines. Most of these highly expressed genes are associated with anti-thrombosis, inhibition of tumor cell mobility, metastasis and angiogenesis. For example, soluble or local platelet-released thrombospondin-1 (TSP-1) may protect unfolded endothelium-bound and subendothelial von Willebrand factor (VWF) from degradation by plasma ADAMTS13, thus securing platelet tethering and thrombus adherence to the inflamed and injured endothelium, respectively (15). Furthermore, runt-related transcription factor 1 (RUNX1) plays a crucial role in the transition of endothelial cells to hematopoietic cells, and in the down-regulation of fetal liver kinase-1. By contrast, Runx1 is weakly expressed in early erythroid cells, and its expression is rapidly extinguished during later stages of erythropoiesis (16,17). In addition, protein tyrosine kinase 2 (PTK2), or Focal adhesion kinase 1, plays a crucial role in generating cell survival signals, as well as the cleavage of FAK during caspase-mediated apoptosis (18). FAK catalytic activities are crucial in promoting VEGF-associated tumor angiogenesis and protease-associated tumor metastasis. Support is growing for the theory that FAK and Src may be therapeutically relevant targets in the inhibition of tumor progression (19).

Discussion

The findings of this study illustrate the importance of the MASPIN gene and protein in regulating the signaling pathway of tumor initiation, promotion and progression, which includes a very complicated and intricate control system with multiple layers that are connected to the expression of the MASPIN gene, including transcription factors, transcription factor binding elements and DNA methylation coalescence.

The expression level of MASPIN was used as an indicator for tumor aggressiveness and metastatic potential. Breast cancer progression from ductal carcinoma in situ, to locally invasive cancer, and finally to lymph node metastasis has been shown to correlate with a stepwise decrease in MASPIN expression (20). Umekita et al reported that the expression of MASPIN predicted poor prognosis in breast cancer patients (21). The down-regulation of the tumor suppressor gene, MASPIN, in breast carcinoma was associated with a higher risk of distant metastasis (20). In this study, we also demonstrate that MASPIN may be an indicator of aggressiveness and metastatic potential for lung cancer cells owing to its dual role in the inhibition of tumor cells.

Previous studies on the regulatory mechanisms of MASPIN have shown that hypermethylation and histone deacetylation lead to silencing of the MASPIN gene in human breast cancer (22,23). Bass et al demonstrated that MASPIN was a non-inhibitory Serpin, which inhibited the migration of tumor and vascular smooth muscle cells (24). Recombinant MASPIN specifically inhibited activators of the cell surface-associated urokinase-type plasminogen and fibrinogen-bound tissue-type plasminogen. Endogenous MASPIN was also a potent inhibitor of the pericellular urokinase-type plasminogen activator and may block tumor invasion and motility by inhibiting localized pericellular proteolysis (25).

Jiang et al reported that MASPIN sensitizes breast carcinoma cells to induced apoptosis (26). Systemic delivery of the MASPIN gene in a syngeneic tumor model inhibited breast tumor progression (27). In this study, comparative proteomic analysis was used to systemically study the protein profile change in a lung cell line.

This study may help to illustrate the function of MASPIN, as well as the regulatory pathway and functional network of MASPIN in lung cancer. However, further studies are required to investigate the functions of MASPIN in further detail.

References

1. 

Z ZouC GaoAK Nagaichp53 regulates the expression of the tumor suppressor gene maspinJ Biol Chem27560516054200010.1074/jbc.275.9.605110692390

2. 

HY ShiW ZhangR LiangModeling human breast cancer metastasis in mice: maspin as a paradigmHistol Histopathol18201206200312507299

3. 

S AbrahamW ZhangN GreenbergM ZhangMaspin functions as tumor suppressor by increasing cell adhesion to extracellular matrix in prostate tumor cellsJ Urol16911571161200310.1097/01.ju.0000040245.70349.3712576872

4. 

S MachtensJ SerthC BokemeyerExpression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical featuresInt J Cancer95337342200110.1002/1097-0215(20010920)95:5%3C337::AID-IJC1059%3E3.0.CO;2-111494236

5. 

JS SchaeferM ZhangRole of maspin in tumor metastasis and angiogenesisCurr Mol Med3653658200310.2174/156652403347951914601639

6. 

ML CherHR Biliran JrS BhagatMaspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasisProc Natl Acad Sci USA10078477852200310.1073/pnas.133136010012788977

7. 

A DokrasJ CoffinL Field6116172006

8. 

DT BrandtC BaarlinkTM KitzingSCAI acts as a suppressor of cancer cell invasion through the transcriptional control of beta1-integrinNat Cell Biol11557568200910.1038/ncb186219350017

9. 

N NeznanovL NeznanovaB AngresAV GudkovSerologically defined colon cancer antigen 3 is necessary for the presentation of TNF receptor 1 on cell surfaceDNA Cell Biol24777785200510.1089/dna.2005.24.77716332174

10. 

K NagasakiC SchemC von KaisenbergLeucine-zipper protein, LDOC1, inhibits NF-kappaB activation and sensitizes pancreatic cancer cells to apoptosisInt J Cancer105454458200310.1002/ijc.1112212712434

11. 

M CicekR FukuyamaDR WelchN SizemoreG CaseyBreast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activityCancer Res6535863595200510.1158/0008-5472.CAN-04-313915867352

12. 

S ParkY LimD LeeIdentification and characterization of a novel cancer/testis antigen gene CAGE-1Biochim Biophys Acta1625173182200310.1016/S0167-4781(02)00620-612531476

13. 

M KimJD GansC NogueiraComparative oncogenomics identifies NEDD9 as a melanoma metastasis geneCell12512691281200610.1016/j.cell.2006.06.00816814714

14. 

RA MerrillAW SeeML WertheimM Clagett-DameCrk-associated substrate (Cas) family member, NEDD9, is regulated in human neuroblastoma cells and in the embryonic hindbrain by all-trans retinoic acidDev Dyn231564575200410.1002/dvdy.20159

15. 

A BonnefoyK DaenensHB FeysThrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13Blood107955964200610.1182/blood-2004-12-485616204318

16. 

RB LorsbachJ MooreSO AngW SunN LennyJR DowningRole of RUNX1 in adult hematopoiesis: analysis of RUNX1-IRES-GFP knock-in mice reveals differential lineage expressionBlood10325222529200410.1182/blood-2003-07-243914630789

17. 

H HiraiIM SamokhvalovT FujimotoS NishikawaJ ImanishiS NishikawaInvolvement of Runx1 in the down-regulation of fetal liver kinase-1 expression during transition of endothelial cells to hematopoietic cellsBlood10619481955200510.1182/blood-2004-12-487215928041

18. 

DD SchlaepferCR HauckDJ SiegSignaling through focal adhesion kinaseProg Biophys Mol Biol71435478199910.1016/S0079-6107(98)00052-2

19. 

JA Bernard-TrifiloST LimS HouDD SchlaepferD IlicAnalyzing FAK and Pyk2 in early integrin signaling eventsCurr Protoc Cell Biol Chapter 14: Unit 1472006

20. 

N MaassM TeffnerF RoselDecline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breastJ Pathol195321326200110.1002/path.94811673829

21. 

Y UmekitaY OhiY SagaraH YoshidaExpression of maspin predicts poor prognosis in breast-cancer patientsInt J Cancer100452455200210.1002/ijc.1050012115529

22. 

BW FutscherMM OshiroRJ WozniakRole for DNA methylation in the control of cell type specific maspin expressionNat Genet31175179200210.1038/ng88612021783

23. 

N MaassM BiallekF RoselHypermethylation and histone deacetylation lead to silencing of the maspin gene in human breast cancerBiochem Biophys Res Commun297125128200210.1016/S0006-291X(02)02136-812220518

24. 

R BassAM FernandezV EllisMaspin inhibits cell migration in the absence of protease inhibitory activityJ Biol Chem2774684546848200210.1074/jbc.C20053220012384513

25. 

H Biliran JrS ShengPleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspinCancer Res6186768682200111751384

26. 

N JiangY MengS ZhangE Mensah-OsmanS ShengMaspin sensitizes breast carcinoma cells to induced apoptosisOncogene2140894098200210.1038/sj.onc.120550712037665

27. 

HY ShiR LiangNS TempletonM ZhangInhibition of breast tumor progression by systemic delivery of the maspin gene in a syngeneic tumor modelMol Ther5755761200210.1006/mthe.2002.060212027560

Related Articles

Journal Cover

March 2012
Volume 3 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu Y, Geng Y, Li K, Wang F, Zhou H, Wang W, Hou J and Liu W: Comparative proteomic analysis of the function and network mechanisms of MASPIN in human lung cells. Exp Ther Med 3: 470-474, 2012
APA
Liu, Y., Geng, Y., Li, K., Wang, F., Zhou, H., Wang, W. ... Liu, W. (2012). Comparative proteomic analysis of the function and network mechanisms of MASPIN in human lung cells. Experimental and Therapeutic Medicine, 3, 470-474. https://doi.org/10.3892/etm.2011.427
MLA
Liu, Y., Geng, Y., Li, K., Wang, F., Zhou, H., Wang, W., Hou, J., Liu, W."Comparative proteomic analysis of the function and network mechanisms of MASPIN in human lung cells". Experimental and Therapeutic Medicine 3.3 (2012): 470-474.
Chicago
Liu, Y., Geng, Y., Li, K., Wang, F., Zhou, H., Wang, W., Hou, J., Liu, W."Comparative proteomic analysis of the function and network mechanisms of MASPIN in human lung cells". Experimental and Therapeutic Medicine 3, no. 3 (2012): 470-474. https://doi.org/10.3892/etm.2011.427